Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19911538 | 0.91 | SLC9A1 (0.45) | SLC9A1METCYP2C19RAB9AALDH1A1 | |
| SCHEMBL19911567 | 0.87 | SLC9A1 (0.61) | SLC9A1METCYP2C19ALDH1A1LMNA | |
| SCHEMBL19848586 | 0.81 | SLC9A1 (0.49) | SLC9A1METCYP2C19ALDH1A1LMNA | |
| SCHEMBL19911488 | 0.81 | SLC9A1 (0.54) | SLC9A1CYP2C19ALDH1A1LMNAMAPK1 | |
| SCHEMBL19848386 | 0.81 | SLC9A1 (0.49) | SLC9A1CYP2C19MEN1KMT2A | |
| SCHEMBL19911391 | 0.79 | MET (0.53) | METRAB9AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL29479890 | 0.79 | SLC9A1 (0.72) | SLC9A1CYP2C19ALDH1A1LMNAMAPK1 | |
| SCHEMBL4339723 | 0.79 | SLC9A1 (0.72) | SLC9A1CYP2C19ALDH1A1LMNAMAPK1 | |
| SCHEMBL19848252 | 0.78 | SMN1; SMN2 (0.52) | SLC9A1METLMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL19848163 | 0.78 | SLC9A1 (0.46) | SLC9A1CYP2C19LMNAALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885MET 4769/4885CYP2C19 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.